Silva, DR;
Dalcolmo, M;
Tiberi, S;
Arbex, MA;
Munoz-Torrico, M;
Duarte, R;
D Ambrosio, L;
... Migliori, GB; + view all
(2018)
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Jornal Brasileiro de Pneumologia
, 44
(2)
pp. 153-160.
10.1590/s1806-37562017000000436.
Preview |
Text
1806-3756-jbpneu-44-02-00153.pdf - Published Version Download (370kB) | Preview |
Abstract
Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the “white plague”, and promising results are being reported.
| Type: | Article |
|---|---|
| Title: | New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1590/s1806-37562017000000436 |
| Publisher version: | https://doi.org/10.1590/s1806-37562017000000436 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0/deed.en |
| Keywords: | Tuberculosis/therapy; Tuberculosis, multidrug-resistant; Extensively drugresistant tuberculosis; Antitubercular agents |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10050363 |
Archive Staff Only
 |
View Item |
